Armoni Brooks

GG
EA7 Emporio Armani Milan
GTD
Injury Illness
Est. Return 4/4/2025
Will sit with illness
GEA7 Emporio Armani Milan
Illness
March 30, 2025
Brooks will not play in Monday's domestic game due to an illness, according to Milan's official website.
ANALYSIS
Brooks is going through a bout with the flu and will sit out Monday as a result. He will have a few days to rest and recover before Milan faces rival Virtus Bologna in Round 33.
Read More News
Per Game
Total
Per 36
EuroLeague Per Game Stats
Loading Per Game Stats...
EuroLeague Total Stats
Loading Total Stats...
EuroLeague Per 36 Stats
Loading Per 36 Stats...
2024
Game Log
Calculate Stats Over Time
Just click on any two dates.
Scoring
DraftKings
Dream11
Loading Game Log...
Advanced Stats
Loading Advanced Stats...
EA7 Emporio Armani Milan Depth Chart
Our full team depth charts are reserved for RotoWire subscribers.
Subscribe Now
More Fantasy News
Rejoins roster
GEA7 Emporio Armani Milan
March 10, 2025
Brooks (illness) put up 27 points, two rebounds, two blocks and seven three-pointers over 21 minutes off the bench in Sunday's domestic game.
ANALYSIS
Subscribe now to instantly reveal our take on this news.
Resting in Round 28
GEA7 Emporio Armani Milan
Illness
March 6, 2025
Brooks will not play Thursday against Fenerbahce, according to Sportando Italia.
ANALYSIS
Subscribe now to instantly reveal our take on this news.
Scores 15 points
GEA7 Emporio Armani Milan
January 10, 2025
Brooks posted 15 points, two rebounds, two assists and three three-pointers in Thursday's win over Maccabi Tel Aviv.
ANALYSIS
Subscribe now to instantly reveal our take on this news.
Reaches double digits again
GEA7 Emporio Armani Milan
October 30, 2024
Brooks posted 17 points, two rebounds, two assists and four three-pointers in Tuesday's loss at Baskonia.
ANALYSIS
Subscribe now to instantly reveal our take on this news.
Matches up with Milan
GEA7 Emporio Armani Milan
June 19, 2024
Brooks signed a two-year contract with Milan, the team announced Wednesday via its official website.
ANALYSIS
Subscribe now to instantly reveal our take on this news.